Cellectar Biosciences Inc. (CLRB), a late-stage clinical biopharmaceutical company, will be presenting new data from its CLOVER-WaM study at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) on Dec.9, 2024.
CLOVER-WaM study is a phase II global pivotal study of the company's lead drug candidate Iopofosine I-131 in relapsed or refractory Waldenstrom macroglobulinemia patients who have received at least two prior lines of therapy, including those who have failed or had a suboptimal response to Bruton tyrosine kinase (BTK) inhibitors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com